PL3082845T3 - Sposoby i kompozycje do leczenia neuropatii obwodowych - Google Patents

Sposoby i kompozycje do leczenia neuropatii obwodowych

Info

Publication number
PL3082845T3
PL3082845T3 PL14872066T PL14872066T PL3082845T3 PL 3082845 T3 PL3082845 T3 PL 3082845T3 PL 14872066 T PL14872066 T PL 14872066T PL 14872066 T PL14872066 T PL 14872066T PL 3082845 T3 PL3082845 T3 PL 3082845T3
Authority
PL
Poland
Prior art keywords
compositions
treatment
methods
peripheral neuropathies
neuropathies
Prior art date
Application number
PL14872066T
Other languages
English (en)
Inventor
Paul Fernyhough
Nigel A. Calcutt
Original Assignee
University Of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Manitoba filed Critical University Of Manitoba
Publication of PL3082845T3 publication Critical patent/PL3082845T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL14872066T 2013-12-20 2014-12-17 Sposoby i kompozycje do leczenia neuropatii obwodowych PL3082845T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919301P 2013-12-20 2013-12-20
PCT/CA2014/051227 WO2015089664A1 (en) 2013-12-20 2014-12-17 Methods and compositions for treatment of peripheral neuropathies
EP14872066.7A EP3082845B1 (en) 2013-12-20 2014-12-17 Methods and compositions for treatment of peripheral neuropathies

Publications (1)

Publication Number Publication Date
PL3082845T3 true PL3082845T3 (pl) 2021-08-02

Family

ID=53401865

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14872066T PL3082845T3 (pl) 2013-12-20 2014-12-17 Sposoby i kompozycje do leczenia neuropatii obwodowych

Country Status (7)

Country Link
US (3) US20170027957A1 (pl)
EP (2) EP3082845B1 (pl)
CN (3) CN106061497A (pl)
CA (1) CA2934578A1 (pl)
ES (1) ES2865624T3 (pl)
PL (1) PL3082845T3 (pl)
WO (1) WO2015089664A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019427489B2 (en) 2019-01-28 2025-03-13 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
WO2020159797A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
CA3133646A1 (en) * 2019-03-26 2020-10-01 Winsantor, Inc. Topical formulations for treatment of peripheral neuropathies
SG10201907677QA (en) * 2019-08-20 2021-03-30 Yin Sze Loh Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.
WO2021120937A1 (zh) * 2019-12-17 2021-06-24 童妍(上海)医疗器械有限公司 转甲状腺素蛋白进入眼内以及在制备滴剂中的应用
US11793754B1 (en) 2022-06-16 2023-10-24 King Abdulaziz University Sodium hypochlorite and chlorhexidine based nanoemulsions and a method of preparation thereof
CN118647404A (zh) * 2022-12-09 2024-09-13 荣昌生物制药(烟台)股份有限公司 Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1147400A1 (ru) * 1981-05-18 1985-03-30 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени поражений периферических нервов
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
GB0602857D0 (en) * 2006-02-13 2006-03-22 Daniolabs Ltd The treatment of sialorrhoea
ES2433568T3 (es) * 2007-10-17 2013-12-11 Curonz Holdings Company Limited Análogos sintéticos de péptidos de regeneración neuronal
NO2632468T3 (pl) * 2010-10-25 2018-05-12
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Also Published As

Publication number Publication date
CA2934578A1 (en) 2015-06-25
EP3895705A2 (en) 2021-10-20
ES2865624T3 (es) 2021-10-15
CN106061497A (zh) 2016-10-26
CN120661657A (zh) 2025-09-19
CN112057626A (zh) 2020-12-11
US20250090545A1 (en) 2025-03-20
US20210267998A1 (en) 2021-09-02
US20170027957A1 (en) 2017-02-02
EP3082845A1 (en) 2016-10-26
EP3082845B1 (en) 2021-02-17
WO2015089664A1 (en) 2015-06-25
EP3082845A4 (en) 2017-10-25
EP3895705A3 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
GB201320723D0 (en) Composition and methods of treatment
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
IL239453A0 (en) Preparations and methods for treating cancer using bacteria
IL244089A0 (en) Diagnostic methods and preparations for the treatment of glioblastoma
IL238177A0 (en) Methods and preparations for the treatment of cancer
PT3021839T (pt) Composições para o tratamento da fibrose
IL239851B (en) Methods and compositions for treating diseases that act to remove myelin
ZA201408056B (en) Compositions and methods for the treatment of mucositis
ZA201408055B (en) Compositions and methods for the treatment of local pain
EP3082427A4 (en) Compositions and methods for treatment of glaucoma
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
SG10201710538XA (en) Compositions and methods for treating skin
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
ZA201509360B (en) Compositions and methods for treatment of stroke
ZA201408065B (en) Compositions and methods for the treatment of diabetes
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
PT2992094T (pt) Composições e métodos para tratamento de diabetes tipo 1
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment
GB201309001D0 (en) Methods for prevention and treatment of preeclampsia